Skip to contentB
BioMarin Pharmaceutical Inc
B
BMRNBioMarin Pharmaceutical Inc Q1 2013 · 10-Q
Revenue$127.93M$127.93M+9.7% vs Q1 2012 Net Income-$39.81M-$39.81MN/M vs Q1 2012 EPS Diluted-$0.31-$0.31N/M vs Q1 2012 Operating Income-$32,921,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
BioMarin Pharmaceutical Inc · CIK 1048477 · Engraved from SEC EDGAR
Free Cash Flowderived-$43,855,000N/M Margins · derivedOperating margin-25.7%−7.0 pt vs Q1 2012
Net margin-31.1%−10.6 pt vs Q1 2012
ended Mar 31, 2013 · filed Apr 29, 2013 · 29 d after period end